Cargando…
A scoring system for AML patients aged 70 years or older, eligible for intensive chemotherapy: a study based on a large European data set using the DATAML, SAL, and PETHEMA registries
In a context of therapeutic revolution in older adults with AML, it is becoming increasingly important to select patients for the various treatment options by taking account of short-term efficacy and toxicity as well as long-term survival. Here, the data from three European registries for 1,199 AML...
Autores principales: | Bérard, Emilie, Röllig, Christoph, Bertoli, Sarah, Pigneux, Arnaud, Tavitian, Suzanne, Kramer, Michael, Serve, Hubert, Bornhäuser, Martin, Platzbecker, Uwe, Müller-Tidow, Carsten, Baldus, Claudia D., Martínez-Cuadrón, David, Serrano, Josefina, Martínez-Sánchez, Pilar, Arbolí, Eduardo Rodríguez, Gil, Cristina, Bergua, Juan, Bernal, Teresa, de la Fuente Burguera, Adolfo, Delabesse, Eric, Bidet, Audrey, Dumas, Pierre-Yves, Montesinos, Pau, Récher, Christian |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9276717/ https://www.ncbi.nlm.nih.gov/pubmed/35821023 http://dx.doi.org/10.1038/s41408-022-00700-x |
Ejemplares similares
-
Long-term survival after intensive chemotherapy or hypomethylating agents in AML patients aged 70 years and older: a large patient data set study from European registries
por: Récher, Christian, et al.
Publicado: (2021) -
Outcome of Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia before Second-Generation FLT3 Tyrosine Kinase Inhibitors: A Toulouse–Bordeaux DATAML Registry Study
por: Bertoli, Sarah, et al.
Publicado: (2020) -
Real-World Outcomes of Patients with Refractory or Relapsed FLT3-ITD Acute Myeloid Leukemia: A Toulouse-Bordeaux DATAML Registry Study
por: Dumas, Pierre-Yves, et al.
Publicado: (2020) -
Azacitidine vs. Decitabine in Unfit Newly Diagnosed Acute Myeloid Leukemia Patients: Results from the PETHEMA Registry
por: Labrador, Jorge, et al.
Publicado: (2022) -
Comparison of the 2022 and 2017 European LeukemiaNet risk classifications in a real-life cohort of the PETHEMA group
por: Sargas, Claudia, et al.
Publicado: (2023)